cyrilzakka/clinical-trials huggingface dataset:
Tart Cherry Supplementation & Gut Microbiome and Inflammation

There has been a rapid increase in researching the use of tart cherry supplements in the past 5 years, particularly for inflammatory conditions. Many formulations of cherry supplements exist, however there has been no comparison between these different types. This is particularly important in the realm of inflammation research because sugar is known to increase the inflammatory response. The pill form of cherry supplementation has no added sugar and is naturally low in sugar (\< 1g) while the juice form is higher from added sugar. Recent work indicates tart cherry consumption can change gut microbiota, which may modify inflammation. The purpose of this study is to look at the effects of taking a cherry supplement, either in capsule or juice form, on the gut microbiome, inflammation, and health-related variables such as blood pressure, glucose regulation and sleep quality.

Participants will consume a tart cherry or placebo product for 30 days and attend 5 visits in the Exercise Physiology Lab at Ohio University over the 30 day period. They will self-collect a stool sample at baseline, 14 days and 30 days after supplementation. Blood samples will be taken at baseline, 7 days, 14 days, and 30 days after supplementation. Throughout the study participates will rate symptoms (stomach, head, etc.), pain and sleep quality using an online survey for which the link will be emailed. Participants will maintain normal diet and exercise routine and to track these for the duration of the study.

Eligibility Criteria:
Inclusion Criteria:

* 18-55 years old
* participate in 150 minutes of exercise per week
* non-smoker
* have no known allergy to cherries or cherry juice
* are not taking food supplements (turmeric/curcumin, cherry products, greens, etc.). -You must have access to the internet and be willing to record your food intake, physical activity and sleep quality/duration during the study.

Exclusion Criteria:

* not 18-55 years old.
* have quit smoking less than one year ago.
* have been diagnosed with a metabolic disorder such as diabetes, thyroid disorder, or high cholesterol.
* are currently being treated for arthritis or an inflammatory condition, such as arthritis, gout, lupus or Sjogren's syndrome.
* are currently being treated for cardiovascular disease, high blood pressure, fibromyalgia, or irritable bowel syndrome.
* are pregnant.
* regularly consume cherries or are allergic to cherries.
* currently use anti-inflammatory medications.
* have used corticosteroids in the last two months.
* are not willing to follow a low polyphenol diet.
* are not willing to have blood drawn on 4 occasions.
* are not willing to provide a stool sample on 3 occasions.
* do not have access to the internet.
Evaluation of the PS100B for the Diagnostic of Stroke With Patients Out of Delay for Thrombolysis or Thrombectomy

Numerous patients are addressed to the Emergency Department for unspecific symptoms which can evoke a stroke, such as vertigo, isolated motor deficit, behavior disorder.

For these patients, when they arrive out of time for specific treatments such as thrombolysis and thrombectomy, the cerebral imagery is not an emergency, but necessary to confirm or invalidate the diagnostic of stroke.

If a biomarker could exclude the diagnostic of stroke, we could avoid an imagery for these patients.

PS100B is a biomarker whose blood level increases in case of stroke. It has already proven a prognostic value. Until now, it hasn't proven a diagnostic value because it take a few hours to increase in the blood.

It could have in prognostic value for patients who have the symptoms for more than 24 hours.

STROkE is a diagnostic, prospective, monocentric study, conducted at University Hospital Center of Poitiers (France).

The aim is to determine the value of PS100B to exclude the diagnostic of a stroke in case of evocative symptoms, for patients who are out of delay for a thrombolysis or a thrombectomy.

Patients eligible are the ones who present to the emergency department with symptoms evocative of stroke for more than 24 hours and less than 4 days. Patients included have a sample of blood withdrawn, in order to measure PS100B blood level.

The diagnostic of stroke is than confirmed or excluded by an adjudication comity, who are unaware of the result of PS100B blood level.

The diagnostic value of PS100B is determined with the help of a ROC curve.


Eligibility Criteria:
Inclusion Criteria:

* Patients presenting at the Emergency Department of the University Hospital Center of Poitiers for the following symptoms, which last since more then 24 hours et less then 4 days :
* sensitive or motor deficit of one or several limbs
* facial paralysis
* impairment of speech
* dysarthria
* vertigo
* impairment of vision
* oculomotor disorder
* diplopia
* free patient, without guardianship or curatorship, or subordination
* patient not objecting to research

Exclusion Criteria:

* head trauma that occured less then 15 days ago
* known cerebral mass or melanoma
* refusal to participate in research
* patient benefiting from enhanced protection, namely: minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection
* pregnant and/or breastfeeding women
Hearing Resources and Outcomes in the Emergency Department (HERO-ED)

The Hearing Resources and Outcomes in the Emergency Department Pilot (HERO-ED Pilot), gathers preliminary data and hones procedures and measures, prior to undertaking HERO-ED. Since the HERO-ED Pilot does not involve random assignment (no control group), it will not test device effectiveness. However, the HERO-ED Pilot will test device acceptability and use. It will also provide preliminary data on, and allow us to fine-tune, the measures of effectiveness that we plan to use in HERO-ED

The objectives are:

1. Measure the feasibility of in-ED hearing screening using HHIE-S and a handheld audiometer, among low-acuity11 ED patients age ≥75 years, by quantifying the proportion of eligible patients who complete hearing screening.
2. Test whether low-acuity older ED patients who screen positive for significant hearing loss (\> 40 dB HL bilaterally and HHIE-S \> 24) and are provided a hearing assistance device (HAD) use that device during the ED visit.
3. Test whether patients who are given a hearing assistance device will report ability as opposed to disability in hearing and understanding, using a six-item questionnaire adapted from a study by Cox et al.
4. Test whether those who are given a hearing assistance device will report being prepared for post-discharge care, using an adapted subset of the Care Transitions Measures (CTM).
5. Assess patient understanding of the HAD survey items within the post-use survey.

Eligibility Criteria:
Inclusion Criteria:

* low acuity clinical presentation (Emergency Severity Index11 triage criteria of 4 or 5, which indicates a high likelihood of being discharged home from the Emergency Department).
* Patients using hearing aids will not be excluded.

Exclusion Criteria:

* Lack of capacity to consent, as defined by the patient's ability to satisfactorily answer the questions outlined in the Evaluation to Sign Consent form (ESC) mentioned in the protocol. A legal representative/family member will not be able to consent for the patient in this study.
Vaping and Smoking Project in People With Schizophrenia

The proposed research will characterize withdrawal among people with schizophrenia who vape daily compared to people with schizophrenia who smoke combustible cigarettes daily, filling critical gaps in the understanding of electronic nicotine delivery systems (ENDS) dependence and contributing to the development of vaping cessation interventions amongst people with schizophrenia, the leading preventable cause of death in the US.

Although withdrawal is considered a key feature of nicotine/tobacco addiction that contributes to difficulty quitting smoking and likely electronic nicotine delivery systems (ENDS; e.g., electronic cigarettes), there is currently no research on ENDS withdrawal in people with schizophrenia. The proposed supplement will conduct a systematic and comprehensive characterization of withdrawal in a sample of people with SCZ who vape daily compared to those who smoke daily, filling gaps in our understanding of ENDS dependence/withdrawal for people with SCZ and contributing to the identification of intervention targets for ENDS use.

Eligibility Criteria:
Inclusion Criteria:

* 6+ months of daily/near-daily nicotine vaping or cigarette smoking
* 200+ ng/mL cotinine on a commercially-available quick screen
* stable antipsychotic medication dose (no changes in past 6 months).

Current Exclusion Criteria:

* intention to quit daily/near-daily vaping/smoking in the next month
* current (2+ days out of the past 7) use of pipe tobacco, hookah/shisha, smokeless tobacco, dissolvable tobacco, nicotine pouches. For vaping group only, current (2+ days out of past 7) use of cigars, cigarillos, or filtered cigars that are filled with tobacco or a mix of tobacco and marijuana
* current use of any smoking cessation medication
* current severe substance dependence other than tobacco/nicotine (including cannabis; NIDA Modified ASSIST of 27+)
* current (past 2 weeks) suicidal ideation with intent and/or plan
* pregnancy (intake urine screen)
* florid psychosis or severe cognitive symptoms (score of ≥5 on PANSS items delusions (P1), hallucinatory behavior (P3), or unusual thought content (G9), conceptual disorganization (P2), abstract thinking (N5), or poor attention (G11) or a score ≥6 on grandiosity (P5) or suspiciousness (P6)
Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis

Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless, in many cases no underlying physical disease is present. According to the literature, in fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform disorders.

We hypothesize that a group of these patients may benefit from antidepressant therapy.


Eligibility Criteria:
Inclusion Criteria:

* prurigo nodularis
* age: 18-70 years
* agreed to participate

Exclusion Criteria:

* younger than 18 or older than 70
* pregnant or lactating women
* chronic diseases: cancer, neurological disorders, diseases that are known to be associated with pruritus such as liver cirrhosis, uremia, etc.
* sensitivity to cipralotam
* psychosis, bi-polar disorder, substance addiction, use of antidepressant in the previous year
* use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine
Spinal Versus General Anesthesia for Laparoscopic Cholecystectomy

The purpose of the study is to assess whether spinal anesthesia is or not superior to the standard general anesthesia for fit patients undergoing laparoscopic cholecystectomy.

Laparoscopic cholecystectomy under regional anesthesia alone has been reported only occasionally in the past; all these reports included patients unfit to receive general anesthesia, mainly patients with severe chronic obstructive airway disease. Regional anesthesia has been used for laparoscopy in fit patients almost exclusively in combination with general anesthesia, in order to extend the analgesic effect during the early postoperative period. Surprisingly, in the era of minimally invasive medicine, regional anesthesia has not gained popularity, and has not been routinely used as a sole method of anesthesia in laparoscopic procedures. It is generally accepted that all laparoscopic procedures are merely a change in access and still require general anesthetic; hence the difference from conventional surgery is likely to be small. This statement is predominantly based on the assumption that laparoscopy necessitates endotracheal intubation to prevent aspiration and respiratory embarrassment secondary to the induction of CO2 pneumoperitoneum which in turn is not well tolerated in a patient who is awake during the procedure. However, it is surprising that regional anesthesia has been successfully used for laparoscopic cholecystectomy in patients unfit to have the procedure under general anesthesia, but has not been tested in fit patients, in whom any presumed risk would be, theoretically, much lower. We have recently shown in a pilot study the feasibility to perform successfully and safely laparoscopic cholecystectomy with low pressure CO2 pneumoperitoneum under spinal anesthesia alone, in fit patients with symptomatic gallstone disease. We have also noticed that spinal anesthesia results in exceptionally minimal postoperative pain. After this pilot study, we designed a controlled randomized trial in order to compare spinal anesthesia with the standard general anesthesia for elective laparoscopic cholecystectomy in fit patients.

Eligibility Criteria:
Inclusion Criteria:

* elective laparoscopic cholecystectomy
* ASA I, II
* BMI\< 30
* normal coagulation profile

Exclusion Criteria:

* acute cholecystitis / cholangitis / pancreatitis
* previous open surgery in the upper abdomen
* contraindication for pneumoperitoneum
* contraindication for spinal anesthesia (ie spinal deformity)
A Study of the Higher Cognitive Functions of the Human Brain With Single-neuron Activity Recording

This study aims to investigate that neural activity of higher cognitve function of human brain with hyperflexible neural electrode-cortex

In this study, patients who need intracerebral puncture and indwelling drainage tube, such as intracerebral hemorrhage and hydrocephalus, will be recruited. Before implanting electrodes, patients will be trained to do higher cognitive function tasks.During operation, electrode will be implanted accompanied by placing drainage tube. After operation, patients will perform tasks, while electrophysiological signals will be collected. At the end of study, electrode will be removed.

Eligibility Criteria:
Inclusion Criteria:

1. aged 18-70 years old.
2. have selective or confine operation indications:spontaneous basal ganglia hemorrhage or lobar hemorrhage that need catheter aspiration and drainage;hydrocephalus that need V-P shunt; need placing ommaya.
3. GCS score 12-15; must be able to communicate with investigators in Mandarin and comply with study requirements.
4. volunteered to participate in this study and sign informed consent.

Exclusion Criteria:

1. have severe cognitive dysfunction.
2. have psychiatric disorders, such as depression, anxiety disorders and schizophrenia.
3. long-term use of special medications, such as hormones, immunosuppressant, and anticoagulants.
4. be allergic to surgery instruments or medications.
5. have general anesthesia, surgery contraindications.
6. have acute cardiac infarction or heart arrest within 6 months.
7. have other neurosurgery contraindications assessed by investigators.
8. lactation or pregnancy.
9. have serious systemic disease or organ dysfunctions that affects study outcome or visits.
10. participate in other ongoing clinical trials.
Multidisciplinary Care Pathway With Electronic Patient Reported Outcomes (ePRO) Post-operative Follow-up of Breast Cancer Surgery Complications to Optimize Patient Quality of Life

This project is a follow-on study of the BEAUTIFY-2 study (NCT04957186). The "BEAUTIFY" (BrEast cAncer qUaliTy of lIfe aFter surgerY) program was built by a committee of experts on the basis of reflections carried out within 2 focus groups. An application was developed to track patient reported outcome measures.

The study investigators now wish to evaluate the feasibility and impact on pain and quality of life of the "BEAUTIFY" care pathway on a larger cohort. The study hypothesis is that multidisciplinary care organization will improve the management and the quality of life post-breast cancer surgery.


Eligibility Criteria:
Inclusion Criteria:

* Breast cancer patient scheduled for surgery
* Patient able to use a connected electronic object and having a tablet or a smartphone with internet access at home.
* The patient must have given their free and informed consent and signed the consent form
* The patient must be a member or beneficiary of a health insurance plan

Exclusion Criteria:

* The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study
* The subject unable to express consent
* It is impossible to give the subject informed information
* The patient is under safeguard of justice or state guardianship
Self-confidence in Midwife Students

Self-confidence is essential during the training of students but in professional practice. Therefore, the training of students must allow its acquisition.

However, the university environment is particularly stressful for students. This stress can lead to depression. Perceived stress refers to the feeling of inability to pass an exam even if the person has the abilities to do so.

aim of the study is to describe the level of self-confidence of midwife students.

Eligibility Criteria:
Inclusion Criteria:

* midwife students
* with or without repeating a grade
* in France
* agreeing to participate in the study

Exclusion Criteria:

-
Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients

The purpose of this study is to assess the safety and tolerability of multiple oral doses of CTX-4430 when administered to cystic fibrosis (CF) patients once-daily (QD) for 15 days.This study will include two dose levels. For each dose level, blood samples will be collected for exploratory PK and PD assay validation. In addition, sputum will be collected for exploratory biomarker analysis. Following multiple dose administration, pulmonary function and exploratory lung clearance index (LCI) measurements will be taken.


Eligibility Criteria:
Inclusion Criteria:

1. Adult male or female, 18 to 55 years of age (inclusive) at the time of screening.
2. Confirmed diagnosis of CF based on the following: positive sweat chloride or sodium value ≥ 60 mEq/L, and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype or a diagnosis of CF made by a specialist in this condition.
3. In the judgment of the Principal Investigator (PI), the patient is medically stable with no change in symptoms, medication, or with clinical laboratory results that in PI opinion are compatible with the diagnosis of either CF or a complication thereof and are judged acceptable for inclusion.
4. Body mass index (BMI) ≥ 17.0 (kg/m2).
5. Non-tobacco/nicotine-containing product user for a minimum of 6 months prior to the first study drug administration.
6. Forced Expiratory Volume (FEV1) of \>50% and \<90% of predicted at screening.
7. Must agree to use adequate method of contraception.

Exclusion Criteria:

1. Patient has displayed any significant clinical/laboratory/radiological/spirometric sign of unstable or unexpectedly deteriorating respiratory disease within 30 days prior to the first study drug administration.
2. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease that depart from the patient's usual baseline level of health as a patient with CF.
3. Has a history of lung transplantation.
4. History or presence of alcoholism or drug abuse within 2 years prior to the first study drug administration.
5. Personal or family history of prolonged QT syndrome; or a QTc interval \>430 msec (males) or \>450 msec (females) using Bazett's formula (QTcB) or deemed clinically significant by the PI.
6. Sitting blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg, unless deemed clinically insignificant by the PI.
7. Pulse is higher than 100 b.p.m or lower than 50 b.p.m. unless deemed clinically insignificant by the PI.
8. Failure to satisfy the PI of fitness to participate for any other reason.
9. In the judgment of the PI, clinically significant hemoptysis (\>30 cc per episode) within the last 180 days.
Follow-Up Study to Assess Implementation of Ultrasound-Guided Regional Anesthesia Skills

The investigators hope to survey anesthesiologists who have participated in a non-CME regional anesthesia workshop at VAPAHCS over the past 4 years on the number and types of nerve block procedures that they performed, nerve localization method (e.g., ultrasound, electrical stimulation, or both), and whether the nerve blocks performed were single-injection or catheter-based.

The investigators expect to recruit approximately 100 participants through the use of an IRB-approved survey and cover letter which will be distributed to anesthesiologists who have participated in a non-CME regional anesthesia workshop at VAPAHCS over the past 4 years. Prospective subjects will provide consent to participate by completing the requested survey. Subjects will not receive monetary remuneration for their participation. Selection for inclusion will not be based on gender, race, or socioeconomic status. There will be no recruitment of participants from vulnerable populations. Participants will receive a link to an online survey and if they prefer an alternate method, the investigators will send the participant the survey in Word document format or survey by telephone. The survey will ask for the number and types of nerve block procedures that the participant performed, nerve localization method (e.g., ultrasound, electrical stimulation, or both), and whether the nerve blocks performed were single-injection or catheter-based.

Eligibility Criteria:
Inclusion Criteria: Anesthesiologists in practice who have participated in a regional anesthesia workshop at VAPAHCS; and willingness to complete a survey.

Exclusion Criteria: Anesthesiologists who have visual, hearing, or other communication impairment that would interfere with survey completion.
A Randomized Controlled Trial on Wound Irrigation in Open Appendectomy.

A large retrospective study compared wound irrigation with antiseptic solution, with antimicrobial agent, and with normal saline in patients undergoing open appendectomy and concluded an evident superiority of antibiotic wound irrigation over both normal saline and antiseptic solution.

The present trial aimed to assess the efficacy of layer-by-layer wound irrigation with gentamicin-saline solution versus saline solution in prevention of incisional SSI after open appendectomy for acute appendicitis. We postulated that irrigation of every layer of the surgical wound separately would help reduce the incidence of incisional SSI by eradication of bacterial contamination of each layer which may occur during delivery, manipulation, and removal of the inflamed appendix through the McBurney's incision.


Eligibility Criteria:
Inclusion Criteria:

* The study included patients of both genders aging between 16 and 65 years who presented to the emergency department with acute appendicitis. Acute appendicitis was diagnosed by clinical examination and intraoperative findings and the diagnosis was confirmed with histopathologic examination of the removed appendix.

Exclusion Criteria:

* Patients with appendicular mass, appendicular abscess, appendicitis associated with generalized peritonitis, acute abdomen due to other causes as revealed intraoperatively, patients with normal appendix as revealed intraoperatively and after histopathologic examination, patients taking long course of steroid therapy or immunosuppressive treatment, and patients unwilling to participate in the trial.